A Single-dose, Open-label Parallel-group Study to Assess the Pharmacokinetics of LCZ696 in Subjects With Hepatic Impairment Compared to Matched Healthy Subjects
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Essential hypertension; Heart failure
- Focus Pharmacokinetics
- Sponsors Novartis; Novartis Pharmaceuticals
- 24 Jul 2017 Results published in the International Journal of Clinical Pharmacology and Therapeutics.
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Nov 2012 New source identified and integrated (European Clinical Trials Database record: EudraCT2012-000983-27).